Neurocrine Expands with Soleno Acquisition
Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, a move that brings Vykat XR, the first approved drug for Prader-Willi syndrome, into its portfolio, according to Dealbreaker. The deal, discussed during a Monday conference call in 2026, allows Neurocrine to add a drug that has seen rapid market uptake since its FDA approval a little more than a year ago. Vykat XR, a once-daily pill, targets hyperphagia in Prader-Willi syndrome, a rare genetic condition caused by the lack of expression of genes regulating hunger and satiety.
Details of the Acquisition and Vykat XR
Soleno Therapeutics reported $190.4 million in Vykat revenue for 2025, including $90 million in the fourth quarter, which helped the company achieve $20.8 million in net income for that year. Neurocrine CEO Kyle Gano stated that the drug shows aspects of a potential blockbuster based on its profile and data reviewed through launch and into 2026. Prader-Willi syndrome leads to morbid childhood obesity and complications such as respiratory issues, cardiovascular problems, and even rupture of the digestive tract, with patients facing a shorter life expectancy and about half of deaths occurring in those aged 18 or younger. Vykat XR, containing an extended-release formulation of diazoxide choline, is thought to activate potassium channels affecting hunger and satiety, according to Dealbreaker.
Neurocrine’s Portfolio Integration
Neurocrine’s existing portfolio includes Ingrezza, which generated $2.5 billion in revenue in 2025, marking a 4.3% increase from the previous year and serving as a treatment for tardive dyskinesia and Huntington’s disease. The acquisition positions Vykat XR alongside Crenessity, a drug approved in late 2024 for congenital adrenal hyperplasia, another rare endocrine disorder. Neurocrine Vice President Samir Siddhanti noted that the company had tracked Soleno and the Prader-Willi space for some time, highlighting Vykat’s fit at the intersection of neuroscience and endocrinology. This strategic addition leverages Neurocrine’s experience in commercializing therapies for rare endocrine disorders.
Challenges in the Prader-Willi Market
The Prader-Willi syndrome market includes competitors like Bright Minds Biosciences, Harmony Biosciences, and Rhythm Pharmaceuticals, but has seen setbacks, such as Acadia Pharmaceuticals halting a Phase 3 study in September of the previous year and Aardvark Therapeutics pausing its trial in February due to cardiac observations. Soleno itself faced stock price declines in August after a report from Scorpion Capital claimed potential safety issues like pulmonary edema and congestive heart failure with Vykat. However, Neurocrine remains confident in the drug’s safety, citing decades of diazoxide use and a favorable risk-benefit profile in clinical testing. Leerink Partners analyst Marc Goodman reported that endocrinologists view Vykat as a valuable option for select patients, though they note limitations due to side effects like hyperglycemia and edema, which restrict its use in patients with obesity and diabetes. Globally, the number of Prader-Willi patients is estimated between 300,000 and 400,000, according to Dealbreaker.
